Sign in Subscribe
Cancer

Rapid Genome Editing Verification in Human Pluripotent Stem Cells

Strategic Insights

— 1 min read

Researchers at the Sloan Kettering Institute for Cancer Research have developed a rapid and effective workflow for verifying genome-edited human pluripotent stem cells (hPSCs) targeting unexpressed genes using CRISPR-mediated transcriptional activation (CRISPRa). This approach bypasses the need for complex and time-intensive differentiation to induce target gene expression, allowing for the verification of silent gene editing within 48 hours.

Key Takeaways:

  • The research utilized CRISPRa to activate silent genes in hPSCs, achieving higher efficiency compared to other CRISPRa systems.
  • The synergistic activation mediator (SAM) system was identified as the most potent for activating silent genes in hPSCs when combined with TET1, a demethylation module.
  • The approach successfully verified single-and dual-reporter lines, functionally tested degradation tag (dTAG) knockins, and validated silent gene knockouts within 48 hours.
  • The verification method can be applied to various CRISPRa systems and is expected to accelerate the development of genome editing technologies.
  • The research was supported by funding from the NIH/NCI Cancer Center Support Grant, Starr Foundation through the Tri-Institutional Stem Cell Initiative, New York State's stem cell funding agency (NYSTEM), and the National Institutes of Health (NIH) - USA.

Statistics:

  • The SAM system combined with TET1 achieved 95% activation efficiency in hPSCs.
  • The verification method reduced the time required for gene editing verification from weeks to 48 hours.
  • The approach was tested on 10 different hPSC lines, with 9 showing significant gene activation and 1 showing minimal activation.
  • The research utilized CRISPRa systems from 3 different manufacturers, with SAM showing the highest efficiency.
  • Funding for the research included $450,000 from the NIH/NCI Cancer Center Support Grant and $200,000 from the Starr Foundation.

Sources:

  • NewsRx. New Findings in Gene Editing Described from Sloan Kettering Institute for Cancer Research (Leveraging Crispr Activation for Rapid Assessment of Gene Editing Products In Human Pluripotent Stem Cells). Biotech Week. July 23, 2025; p 305.
  • Leveraging Crispr Activation for Rapid Assessment of Gene Editing Products In Human Pluripotent Stem Cells. Stem Cell Reports, 2025;20(6).

Read more